Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.

Tumori - 24 Jul 2015

Giuliani Jacopo, Martelli Salvatore, Remo Andrea, Bonetti Andrea

Abstract excerpt

The malignant behavior of non-small cell lung cancer (NSCLC) is caused by different driver mutations, which may include alterations in the epidermal growth factor receptor (EGFR) signaling pathway. Activating mutations in exons 19 or 21 of EGFR in NSCLC are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. However, approximately 10% of NSCLC patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Administration Schedule
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Fatal Outcome

Share to Gefitinib

Share to Pleural Effusion

Share to Protein-Tyrosine Kinases

Share to Quinazolines

Share to Tomography, X-Ray Computed

Source

Identifiers

PMID: 25953440
DOI: 10.5301/tj.5000317

Genes

EGFR
ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.PMID 25953440Read ↗

Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma.Semantic proximity Read ↗

Simultaneous Acquisition of T790M Mutation and SCLC Transformation during Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma: A Rare Case Report.Semantic proximity Read ↗

[Advances in research on primary resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer patients].Semantic proximity Read ↗

Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update.Semantic proximity Read ↗

The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation.Semantic proximity Read ↗

Savolitinib monotherapy exerted significant benefit in a non-small cell lung cancer patient with osimertinib resistance harboring primary EGFR L858R mutation and MET amplification: a case report.Semantic proximity Read ↗

The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients.Semantic proximity Read ↗

Transformation of non-small cell lung cancer into small cell lung cancer in a patient with advanced lung cancer: a case report.Semantic proximity Read ↗

A case of different gene mutations in primary and metastatic lesions after EGFR-TKI treatment of lung cancer.Semantic proximity Read ↗

Sequential small cell transformation and T790M mutation in an epidermal growth factor-mutant lung adenocarcinoma: A rare occurrence with significant management implications.Semantic proximity Read ↗

Association between advanced NSCLC T790 M EGFR-TKI secondary resistance and prognosis: A observational study.Semantic proximity Read ↗

Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.